Page 4 - Zydus Lifesciences

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for Rs 2,430 cr

Zydus will file a mandatory cash tender offer for the remaining shares of Amplitude at the same purchase price of €6.25 per share

Zydus Lifesciences to buy 86% stake in Amplitude Surgical for $280 million

Zydus Lifesciences on Tuesday said it has entered into exclusive negotiations to acquire a majority stake in France-based Amplitude Surgical for 256.8 million euros. The company has entered into negotiations with PAI Partners, Amplitude Surgical's management, as well as two minority shareholders to acquire 85.6 per cent of the company's share capital, the Ahmedabad-based drug maker said in a regulatory filing. Purchase consideration amounts to 256.8 million euros for 85.6 per cent of the outstanding shares and voting rights of Amplitude Surgical, it added. Amplitude Surgical is a European MedTech leader in high-quality, lower-limb orthopaedic technologies. The company provides numerous value-added innovations to best meet the needs of patients, surgeons and healthcare facilities. This includes the design and development of knee and hip prostheses, which are implanted in place of damaged or worn-out joints. In fiscal year ended June 30, 2024, Amplitude Surgical generated sales of

Zydus Lifesciences shares fly 7% as USFDA okays cancer drug Dasatinib

The uptick in Zydus Life share price came after the company announced that it has received final approval from the USFDA to manufacture Dasatinib tabs, 20 mg, 50 mg, 70 mg, 80 mg, 100 mg, and 140 mg

Zydus launches affordable, breakthrough drug for transplant patients

Zydus Lifesciences on Wednesday said it has launched ANVIMO, a breakthrough medication for the prevention of Cytomegalovirus infection for haematopoietic stem cell transplant and kidney transplant patients. ANVIMO (Letermovir) will be available in dosages of 240 mg and 480 mg, the drug firm said in a statement. CMV infection remains one of the most serious complications in transplant patients, often leading to graft failure, decreased survival and prolonged hospital stays. Traditional CMV treatments, such as ganciclovir and valganciclovir, have notable limitations, including toxicity and bone marrow suppression. Letermovir provides a safer, well-tolerated, and effective alternative, offering superior safety and reduced side effects while improving transplant outcomes. "The introduction of ANVIMO marks a new era in bone marrow transplant and kidney transplant care in India. By making this critical therapy affordable and accessible, we are reinforcing our commitment to delivering ..

Zydus Lifesciences to develop world's first dual vaccine for typhoid

Typhoid and shigellosis remain serious public health threats, particularly in low-resource settings

Zydus launches vaccine for protection against new strain of influenza virus

Zydus Lifesciences on Wednesday said it is introducing a vaccine for protection against new strain of influenza virus. The company is introducing country's first flu protection quadrivalent influenza virus vaccine as per WHO recommended composition, the Ahmedabad-based drug major said in a statement. Zydus's Quadrivalent Inactivated Influenza vaccine VaxiFlu-4 will offer seasonal protection against four new virus strains, it added. A quadrivalent vaccine, by covering strains of both influenza A and influenza B, provides a broader protection and significantly reduces the risk of vaccine mismatch, it said. The vaccine has been cleared by the Central Drug Laboratory (CDL), the drug maker said. "Preventives are the key to public health in both the developing and the developed world and vaccines have the potential to improve the quality of life," Zydus Lifesciences Managing Director Sharvil Patel said. In India, there is a pressing need for access to affordable, high-quality vaccines

Zydus Lifesciences, Granules, Glenmark: Nifty Pharma up despite weak market

Nifty Pharma among others has gained 0.8 per cent in trade, logging an intra-day high at 20,550.6

Pharma sector can deliver 100 new drugs by 2047: Zydus chairman

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday. Speaking at an event here, he stressed the need for innovation, capability building, and a focus on societal benefit. "I believe India can deliver 100 new chemical entities or new drugs to the world by 2047 and off course, it will require effort," Patel said while speaking at the SOUL leadership conclave 2025. He termed it a myth that drug discovery requires a billion dollars while emphasising that it is possible with the right approach. Patel also asserted that the people working in an organisation are the most valuable resource and pitched for an environment where people love to work. He also emphasised the evolving nature of leadership, highlighting the importance of humility, vision, and a global perspective. Patel also shared experiences, including the Prime Minister's proactiv

Nifty Pharma tanks 3% on Trump's tariff threat; Zydus, Lupin down upto 10%

The decline in pharma stocks followed comments from President Donald Trump, who indicated that the US may impose tariffs of around 25 per cent on pharmaceutical, automobile, and semiconductor imports

Zydus Life up 3% on mixed Q3, mcap tops Rs 1 trn; analysts split on outlook

Despite challenges from a lower-margin product mix, Zydus Life benefitted from forex gains and a favourable tax rate, which led to a PAT beat, analysts said

Zydus Lifesciences Q3 results: Profit soars 29.6%, revenue grows 16.9%

The company's India business, comprising both formulations and consumer wellness divisions, contributed 38 per cent of consolidated revenue

Zydus Life Q3 results: Net profit jumps 30% to Rs 1,024 cr on strong demand

The United States is the company's biggest market accounting for 47 per cent of total revenue, followed by India

Zydus Life up 2% on USFDA nod for Phase II(b) clinical trial for Usnoflast

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

These 5 Nifty Next 50 stocks can rally up to 17%; suggest tech charts

Technical chart shows that the Nifty Next 50 index looks weak and could slide towards 58,670 - implying an over 11% fall from present levels, whereas on the upside can jump by 6% to 70,200 levels.

Zydus Lifesciences rises 5% on signing agreement with CVS Caremark; Details

CVS Caremark will add Zydus' ZituvioTM and combination products to its template formulary starting January 1, 2025

Zydus Lifesciences net profit up 14% on strong India, US formulations biz

The growth is attributed to strong performances across domestic and international formulations, and double-digit growth in the consumer wellness business

Zydus Lifesciences Q2 result: Net profit rises 13.8% to Rs 911.2 crore

Zydus Lifesciences Ltd on Tuesday reported a 13.8 per cent rise in consolidated net profit at Rs 911.2 crore in the second quarter ended September 30, 2024. The company had posted a consolidated net profit of Rs 800.7 crore in the corresponding period of the last fiscal year, Zydus Lifesciences Ltd said in a regulatory filing. Consolidated revenue from operations stood at Rs 5,237 crore, as compared to Rs 4,368.8 crore in the year-ago period, it added. "Sustained growth momentum across our businesses along with enhanced profitability drove our strong Q2 performance. Execution success of our differentiated pipeline in the US and outperformance of our India geography business were particularly noteworthy," Zydus Lifesciences Managing Director Sharvil Patel said. India geography comprising formulations as well as consumer wellness businesses registered revenues of Rs 1,944.4 crore, up 10 per cent year-on-year (y-o-y). The US formulations business registered revenue of Rs 2,416 8 cror

WHO approves Zydus Lifesciences' typhoid vaccine for UN procurement

Typhoid affects an estimated 11 to 21 million people annually, leading to between 117,000 and 161,000 deaths

Zydus Lifesciences gets USFDA nod for generic schizophrenia treatment drug

Zydus Lifesciences Ltd on Thursday said it has received final approval from the US health regulator to manufacture its generic version of Paliperidone extended-release tablets, used to treat schizophrenia. The approval by the US Food and Drug Administration (USFDA) is for Paliperidone extended-release tablets of strengths 1.5 mg, 3 mg, 6 mg, and 9 mg, Zydus Lifesciences said in a regulatory filing. These tablets will be produced at the group's manufacturing site at SEZ, Ahmedabad, it added. Paliperidone extended-release tablets are indicated for the acute and maintenance treatment of schizophrenia, acute treatment of schizoaffective disorder as monotherapy and acute treatment of schizoaffective disorder as an adjunct to mood stabilisers and/or antidepressants, the company said.

Stocks To Watch: SBI, Mankind, Adani Enterprises, Dr. Reddy's, Zydus Life

Stocks to watch: SBI plans to open 600 new branches this fiscal year to expand its reach in emerging residential areas, said its chairman and managing director CS Setty.